Join
Live feed
·
PRReleasevia Quantisnow
BioAge Labs Inc. logo

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

ByQuantisnow·Wall Street's wire, on your screen.
BIOA· BioAge Labs Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIOA (BioAge Labs Inc.) and more on Quantisnow.